Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of…

Pegcetacoplan also demonstrated statistical significance on the key secondary endpoints of composite renal endpoint, which combines proteinuria reduction and estimated glomerular filtration rate (eGFR) stabilisation, and proteinuria reduction of at least 50% compared to baseline, as well as nominal significance on the histological endpoint of reduction in C3c staining on kidney biopsy and stabilisation of kidney function as measured by eGFR compared to placebo. Pegcetacoplan also demonstrated...

Consello Capital Acquires EHE Health, the Leader in Employer-Based Preventive…

"EHE has built an excellent reputation and demonstrated its ability to partner with some of the world's largest companies. It offers a compelling value proposition in the form of bettering people's lives and consistently generates a positive return on investment for employers seeking to lower healthcare costs," said Peter Morrow, Managing Partner of Consello Capital. "We are excited to partner with the EHE team and help them continue to grow." "EHE has built an excellent…

Endo Presents New Data at the American Podiatric Medical Association Annual…

"We're pleased to share new data about plantar fibromatosis with healthcare providers who care for and treat patients with the condition, which can be painful and burdensome," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo. "Encouraged by the clinical study data being presented at APMA, we are advancing our Phase 3 clinical study to explore a potential nonsurgical option in the future." "We're pleased to share new data…

iTeos Reports Second Quarter 2024 Financial Results and Provides Business…

- Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Pro forma cash and investment balance of $714.4 million as of June 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Aug.08, 2024(GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage...

Breaking Barriers: "Salvează o inimă" Association: €200,000 for homeless people…

I felt completely helpless, I regretted not being able to do more. The idea of setting up a shelter came somehow as a saving solution for those forced to live on the streets. It was very important to buy a house. Later we found out the history of the building and we were surprised, but also impressed. The former house of Ceaușescu became a shelter for the completely helpless - a beautiful transformation!" Ionela recounts. I felt completely helpless, I regretted not being able to do more...

/C O R R E C T I O N -- Unilabs/

Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N's Precivity portfolio of blood tests on an exclusive basis in Europe, including Norway, Switzerland, and the United Kingdom. The agreement will also provide access in Peru, Saudi Arabia, and the United Arab Emirates. Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N'sPrecivity portfolio of blood tests on an exclusive basis inEurope, including...

Orion Group Half-Year Financial Report January–June 2024

ORION CORPORATIONHALF-YEAR FINANCIAL REPORT 1–6/20248 AUGUST 2024 at 12:00 EESTOrion Group Half-Year Financial Report January–June 2024Net sales totalled EUR 636.7 (January–June 2023: 567.5) million Operating profit was EUR 121.8 (102.0) millionBasic earnings per share were EUR 0.68 (0.57)Cash flow from operating activities per share was EUR 0.98 (0.27)The outlook for 2024 was upgraded after the reporting period on 1 July 2024: Net sales are estimated to be EUR 1,440...

WuXi Biologics and Medigene Enter into a Research Collaboration for…

"We are confident that Medigene's known capabilities in generating potential best-in-class 3S TCRs for TCR-T cell therapies can also be applied to non-cellular modalities," said Selwyn Ho, CEO of Medigene. "As such, we are delighted to be able to partner with WuXi Biologics with their validated anti-CD3 mAb, and its industry leading TCE platform and WuXiBody™ to support our strategy to apply Medigene's TCRs into new modalities, such as TCR-TCEs for use in patients where additional…

Orion Corporation's financial reporting and Annual General Meeting in 2025

ORION CORPORATIONSTOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 8 AUGUST 2024 at 9.45 EEST Orion Corporation's financial reporting and Annual General Meeting in 2025 Orion Corporation will publish its Financial Statement Release 2024 on Tuesday, 25 February 2025.The publication dates of the Interim Reports and the Half-Year Financial Report in 2025 are as follows: Interim Report January-March 2025Wednesday 23 April 2025Half-Year Financial Report...

Press Release: Sarclisa induction treatment demonstrated significantly improved…

Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplantSarclisa (isatuximab) in combination with standard-of-care lenalidomide, bortezomib, and dexamethasone (RVd) during 18-week induction treatment followed by transplant resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy, regardless of...

Sandoz reports second-quarter sales and half-year 2024 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD)Half-year net sales of USD 5.0 billion, up 7% in constant currencies (up 6% in USD)Half-year core EBITDA margin[2] of 17.5%, a strong 210 basis point improvement versus H2 2023, driven by favorable biosimilars mix;...

Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for…

The contract will help replenish inventory of bulk vaccine required for future manufacturing and supply of freeze-dried vaccines.COPENHAGEN, Denmark, August 8, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that it has received a new order valued at USD 156.8 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to manufacture...

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's…

On 6 August, the Center for Drug Evaluation (CDE) of the NMPA approved the clinical trial application for WGc-043 injection, allowing the initiation of Phase I clinical trials. This dual approval further validates WestGene's expertise in core mRNA technologies such as delivery vectors and sequence design, and accelerates the commercialisation of effective and low-toxicity anti-tumour mRNA vaccines worldwide. On 6 August, the Center for Drug Evaluation (CDE) of the NMPA approved the clinical...

LG UNVEILS NEW THERMA V™ R290 MONOBLOC MODELS WITH ADVANCED COMPRESSOR AT IFA…

With the mandatory implementation of Nearly-Zero Energy Buildings (NZEB) standards across Europe,1 AWHPs are gaining popularity for their ability to reduce carbon emissions and handle energy supply uncertainties. For new constructions, medium- and small-capacity models are more suitable, making LG's new 7- and 9 kW models ideal for the European market. Additionally, LG is establishing an Air Solution Research and Development (R&D) Lab in Frankfurt, Germany, to develop high-efficiency…

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first…

Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001) 1Fabhalta is an inhibitor of the alternative complement pathway, activation of which is thought to contribute to the pathogenesis of IgAN 1-4Despite current standard of care, up to 50% of IgAN patients with persistent...

Endo to Host Investor Call on Second Quarter 2024 Financial Results

A replay of the webcast will be available within 24 hours at investor.endo.com. A replay of the webcast will be available within 24 hours atinvestor.endo.com. About EndoEndo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more atwww.endo.comor...

Fierce Competition and Technological Innovation Drive Diabetes Care Devices…

As awareness around diabetes increases, so do diagnosis rates. Global screening tests for early detection of T2D in adults have shown significant sensitivity and specificity, leading to higher diagnosis rates and, consequently, greater demand for diabetes care devices. As awareness around diabetes increases, so do diagnosis rates. Global screening tests for early detection of T2D in adults have shown significant sensitivity and specificity, leading to higher diagnosis rates and, consequently,...

Genmab Announces Financial Results for the First Half of 2024

Genmab Updates 2024 Financial Guidance

Label-Free Detection Market worth $747 million by 2029 driven by Technological…

LILYSILK Celebrates 14 Years of Elegance and Sustainability with Eco-Conscious…

Cambridge Medical & Rehabilitation Center Accredited by The Commission on…

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on…

Recursion and Exscientia Enter Definitive Agreement to Create a Global…

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of…

Consello Capital Acquires EHE Health, the Leader in Employer-Based Preventive…

Endo Presents New Data at the American Podiatric Medical Association Annual…

iTeos Reports Second Quarter 2024 Financial Results and Provides Business…

Breaking Barriers: "Salvează o inimă" Association: €200,000 for homeless people…

/C O R R E C T I O N -- Unilabs/

Orion Group Half-Year Financial Report January–June 2024

WuXi Biologics and Medigene Enter into a Research Collaboration for…

Orion Corporation's financial reporting and Annual General Meeting in 2025

Press Release: Sarclisa induction treatment demonstrated significantly improved…

Sandoz reports second-quarter sales and half-year 2024 results

Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for…

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's…

LG UNVEILS NEW THERMA V™ R290 MONOBLOC MODELS WITH ADVANCED COMPRESSOR AT IFA…

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first…

Endo to Host Investor Call on Second Quarter 2024 Financial Results

Fierce Competition and Technological Innovation Drive Diabetes Care Devices…